Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tianchen Biopharmaceuticals

Request full access

An innovative drug research and development enterprise focusing on biological macromolecules

Huangpu, ChinaFounded 2020Biotech & Life Sciences

About Tianchen Biopharmaceuticals

Based in Shanghai, Tianchen Biopharmaceuticals (also known as Longbio Pharma) is a clinical-stage biopharmaceutical company established in 2018, concentrating on the research and development of innovative antibody and fusion protein drugs. The company was co-founded by Dr. Heng Liu and Dr. Bill Nai-chau Sun. Dr. Liu, the current CEO, previously served as the Director of Pre-clinical and CMC at Generon, where he was involved in the development of several innovative drugs. Dr. Sun is a serial entrepreneur who co-founded Tanox Inc. in 1986, which was later acquired by Genentech for $919 million. He was the main inventor of the first-generation anti-IgE antibody, Omalizumab (Xolair®), a blockbuster drug for asthma and allergic diseases.

The company's business model is centered on creating a pipeline of proprietary assets and then out-licensing them to larger biopharma partners who manage late-stage development and commercialization. Tianchen Biopharmaceuticals develops treatments for autoimmune disorders, allergies, and complement-mediated diseases, such as nephrology, dermatology, and ophthalmology. The company's revenue generation relies on licensing fees, milestone payments from partners, and potential future royalties on product sales. Since its inception, the firm has secured significant funding, raising a total of $41.5 million over five rounds, including a recent Series C round of $27.8 million in June 2025, with investors like Qiming Venture Partners and Honghui Fund.

Tianchen Biopharmaceuticals' lead product candidate is LP-003, a next-generation anti-IgE antibody for treating allergic diseases. LP-003 is designed to have a higher binding affinity and a longer half-life than existing treatments like Omalizumab, potentially allowing for less frequent dosing—from once every 2-4 weeks to once every 3-6 months. Currently in Phase III studies, LP-003 is being investigated for various indications, including allergic rhinitis, chronic spontaneous urticaria (CSU), and asthma. Another key pipeline asset is LP-005, a bifunctional complement inhibitor targeting both C3 and C5 for complement-mediated disorders. This candidate is in Phase II trials for conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and IgA Nephropathy (IgAN).

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
50.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit Jun 2026 $0 — Undisclosed ↗
SERIES B✓Equity / VC May 2025 — — Highlight Capital · Lingang Group ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Tianchen Biopharmaceuticals website traffic

Latest recorded traffic for Tianchen Biopharmaceuticals is 1.4K monthly website visits, up 55.6% over the last three months. Tianchen Biopharmaceuticals's team grew 40% over the past year.

Latest monthly visits1.4K 3-month web change+55.6% 1-year team growth+40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tianchen Biopharmaceuticals in the Huangpu ecosystem

Live from Dealroom

The Tianchen Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Everstone
  • Oriental Fortune Capital
  • Hefei Hongda
  • Huzhou Youcheng
  • Shanzheng Innovation
  • Changshu Guofa Venture Capital
  • Qiming Venture Partners
  • Highlight Capital
  • Lingang Group
Employees 7 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China66.7%
🇬🇧 United Kingdom33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tianchen Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tianchen Biopharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.